Clinuvel Pharmaceuticals Ltd CLVLF:OTCPK

RT Quote | Exchange | USD
Last | 10/15/21 EDT
30.20quote price arrow down-0.20 (-0.66%)
Volume
200
52 week range
14.42 - 30.89
Loading...
  • Open30.20
  • Day High30.20
  • Day Low30.20
  • Prev Close30.40
  • 52 Week High30.89
  • 52 Week High Date09/30/21
  • 52 Week Low14.42
  • 52 Week Low Date11/04/20

Key Stats

  • Market Cap1,505.75M
  • Shares Out49.41M
  • 10 Day Average Volume2,710
  • Dividend0.02
  • Dividend Yield0.06%
  • Beta-
  • YTD % Change76.4

KEY STATS

  • Open30.20
  • Day High30.20
  • Day Low30.20
  • Prev Close30.40
  • 52 Week High30.89
  • 52 Week High Date09/30/21
  • 52 Week Low14.42
  • 52 Week Low Date11/04/20
  • Market Cap1,505.75M
  • Shares Out49.41M
  • 10 Day Average Volume2,710
  • Dividend0.02
  • Dividend Yield0.06%
  • Beta-
  • YTD % Change76.4

RATIOS/PROFITABILITY

  • EPS (TTM)0.37
  • P/E (TTM)81.06
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date09/03/2020
  • Div Amount0.025
  • Split Date-
  • Split Factor-

Latest On Clinuvel Pharmaceuticals Ltd

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. The Company’s principal activity consists of commercializing and distribution in Europe and the United States of its drug candidate SCENESSE for the treatment of a rare, genetic metabolic disorder erythropoietic...
Willem Blijdorp
Non-Executive Chairman
Philippe Wolgen M.D.
Chief Executive Officer
Darren Keamy
Chief Financial Officer
Address
L 11 535 Bourke St
Melbourne, VIC
3000
Australia